Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials

2013 ◽  
Vol 133 (4) ◽  
pp. 1006-1015 ◽  
Author(s):  
Frederik Marmé ◽  
Julia Aigner ◽  
Justo Lorenzo Bermejo ◽  
Peter Sinn ◽  
Christof Sohn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Phase I ◽  
Survival Data ◽  
Primary Breast Cancer ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Is It Definitely Clear That Long-Term Survival after Breast Cancer Surgery Is Not Affected by Anaesthetics?

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3390
Author(s):  
Mats Enlund
Keyword(s):  
Breast Cancer ◽  
Survival Data ◽  
Retrospective Studies ◽  
Breast Cancer Surgery ◽  
Breast Cancer Patients ◽  
Term Survival ◽  
Long Term Survival ◽  
Significant Difference ◽  
One Year

Retrospective studies indicate that cancer survival may be affected by the anaesthetic technique. Propofol seems to be a better choice than volatile anaesthetics, such as sevoflurane. The first two retrospective studies suggested better long-term survival with propofol, but not for breast cancer. Subsequent retrospective studies from Asia indicated the same. When data from seven Swedish hospitals were analysed, including 6305 breast cancer patients, different analyses gave different results, from a non-significant difference in survival to a remarkably large difference in favour of propofol, an illustration of the innate weakness in the retrospective design. The largest randomised clinical trial, registered on clinicaltrial.gov, with survival as an outcome is the Cancer and Anesthesia study. Patients are here randomised to propofol or sevoflurane. The inclusion of patients with breast cancer was completed in autumn 2017. Delayed by the pandemic, one-year survival data for the cohort were presented in November 2020. Due to the extremely good short-term survival for breast cancer, one-year survival is of less interest for this disease. As the inclusions took almost five years, there was also a trend to observe. Unsurprisingly, no difference was found in one-year survival between the two groups, and the trend indicated no difference either.

New prognostic factors associated with long-term survival in node-negative breast cancer patients

Breast Cancer ◽  
1999 ◽  
Vol 6 (4) ◽  
pp. 370-377 ◽  
Author(s):  
Takao Kato ◽  
Tsunehito Kimura ◽  
Nobue Takami ◽  
Ryuhei Miyakawa ◽  
Schinichi Tanaka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Term Survival ◽  
Node Negative ◽  
Long Term Survival ◽  
Factors Associated ◽  
Node Negative Breast Cancer

Neoadjuvant epirubicin, gemcitabine, and docetaxel for primary breast cancer: Survival and prognostic factors in two consecutive neoadjuvant phase I/II trials.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1096-1096
Author(s):  
Frederik Marme ◽  
Justo Lorenzo Bermejo ◽  
Hans-Peter Sinn ◽  
Peter Lichter ◽  
Florian Schuetz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Phase I ◽  
Survival Data ◽  
Primary Breast Cancer ◽  
Univariate Analysis ◽  
Pathologic Complete Response ◽  
Small Sample ◽  
Ki 67 ◽  
Significant Difference

1096 Background: We previously reported primary end points of two consecutive phase I/II trials which evaluated two different schedules of neoadjuvant gemcitabine (G), epirubicin (E) and docetaxel (Doc) for primary breast cancer. Here we report mature survival data and evaluate prognostic factors for disease-free (DFS) and overall survival (OS). Methods: 151 patients were treated in two phase I/II trials of G, E and Doc as neoadjuvant chemotherapy (NAC) for T2-4 N0-2 M0 PBC between Feb. ’02 and Dec. ’04. Patients were treated with six cycles of GEDoc (G 800mg/m2 day (d) 1+8, E 60-90mg/m2 d 1, Doc 60-75mg/m2 d 1 every three weeks) or five cycles of G 1250mg/m2 plus E 90-100mg/m2 every two weeks followed sequentially by four cycles of Doc 80-100mg/m2 every two weeks (GEsDoc). Pathologic complete response (pCR), clinical/pathological factors were correlated with DFS and OS. Results: There was no significant difference in DFS or OS between patients in the GEDoc and GEsDoc trial (DFS: Hazard ratio (HR) 1.13, p=0.67; OS: HR 1.06, p=0.88) with a 5-year DFS and OS of 72 vs 74% and 85 vs 86%, respectively. In an univariate analysis pCR unexpectedly was associated with a worse OS (HR 3.11; p= 0.007). HR for DFS showed a similar but non-significant trend (HR 1.78; p=0.1). Molecular subtypes (OS: HR [lum B] 3.17; [triple negative] 5.81; [HER2] 11.5; p=0.002), negative estrogen receptor (ER) status (OS: HR 3.14; p=0.002) and Ki-67 >20% (OS: HR 5.41; p=0.001) were all significantly associated with DFS and OS. The recently published CPS-EG score (Mittendorf 2011) was also significantly correlated with OS (p=0.006) and DFS (p=0.0006). In a multivariate analysis high Ki-67 was the only significant predictor of OS (HR 10.4; p=0.0026) whereas molecular subtype (p=0.05) and Ki-67 (p=0.04) were significantly associated with DFS. Conclusions: These results raise caution on the reliability of pCR as a single surrogate marker for survival in trials with small sample sizes. Our results emphazise the role of additional factors, esp. Ki-67 and subtypes. Integrative scores based on clinical and pathologic stage as well as tumor biology, might be more reliable predictors of survival.

Long-term survival of women with breast cancer with ≥10 lymph nodes at diagnosis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11575-e11575
Author(s):  
Ludimila Cavalcante ◽  
Simon B. Zeichner ◽  
Gabriel P Suciu ◽  
Ana L. Ruiz ◽  
Alicia Hirzel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Term Survival ◽  
Long Term Survival ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph

e11575 Background: Axillary lymph node status is one of the most important prognostic factors in patients with breast cancer, and those with more than ten metastatic lymph nodes at diagnosis have a decreased overall survival. The purpose of this study is to better characterize the clinical course of this high-risk, poorly described patient population and determine the factors associated with long-term survival. Methods: A retrospective cohort analysis of all breast cancer patients with greater than ten metastatic lymph nodes diagnosed at Mt. Sinai Medical Center from January 1990 to December 2007 (n= 175). Descriptive frequencies, overall median survival (OMS), 5- and 10-year survival were calculated for standard prognostic factors and treatment variables. Univariate statistical analysis was performed, followed by a multivariate prognostic analysis for time-to-event data, using the Cox and extended Cox regression model. Results: The majority of patients were non-Hispanic white females between the ages of 56-70, diagnosed between 1990-1999, with tumors between 2-5 cm and 10-15 metastatic lymph nodes. Most were ER/PR positive, HER2 negative, and treated with surgery, chemotherapy, radiation and hormonal therapy. The OMS was 94 months (CI = 69-114) with 5- and 10-year survival rates of 64.3 and 41.6%, respectively. Ages between 21-45 years (OMS of 187 months, p = 0.03), tumors less than 2 cm (146 months (95% CI = 85-198), p = 0.02), ER positivity (131 months (95% CI = 94-157) vs. 39 months (95% CI = 27-59), p = 0.0003) and treatment received between 2000-2003 (98 months (95% CI = 55-133), p = 0.02) were all associated with significantly improved survival. Conclusions: Over the past decade there were significant gains in the long-term survival of breast cancer patients with greater than ten positive nodes at diagnosis, possibly due to improvements in multimodality therapy, such as the introduction of taxanes, although stage migration may be another contributing factor. Our study further showed an encouraging survival for ER positive patients and a dismal one for ER negative patients, highlighting the need for new targeted therapies directed towards ER negative tumors.

scholarly journals Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 525
Author(s):  
Daphne W. Dumoulin ◽  
Robin Cornelissen ◽  
Koen Bezemer ◽  
Sara J. Baart ◽  
Joachim G. J. V. Aerts
Keyword(s):  
Phase I ◽  
Phase Ii ◽  
Survival Data ◽  
Ex Vivo ◽  
Tumor Cell Line ◽  
Autologous Tumor ◽  
Term Survival ◽  
Long Term Survival ◽  
Three Phase

Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if untreated, poor survival of approximately nine months from diagnosis. Until recently, phase II–III immunotherapy trials did not show any significant benefit. The lack of immunotherapy efficacy can be explained by the fact that mesothelioma is a tumor with an “immune desert” phenotype, meaning a non-inflamed tumor characterized by low T-cell infiltration. By administration of DCs, which were ex-vivo cultured, exposed to (tumor-associated) antigens, and subsequently activated, this “immune desert” phenotype might be turned into an “inflamed” phenotype. Three phase I/II studies have been performed and published using activated DCs, which support this concept. We here report on the long-term survival of patients treated with DCs in three phase I/II studies. Methods: Survival data of the phase I/II trials using DC therapy in MPM patients were obtained and subsequently analyzed. In the first two trials, DCs were loaded with autologous tumor lysate. In the third trial, DCs were loaded with allogeneic mesothelioma tumor cell line lysate. Results: In the three studies combined, 29 patients with MPM were treated with DC vaccination between 2006 and 2015. At data cut-off, the median OS was 27 months (95% CI: 21–47 months). OS at 2 years was 55.2% (95% CI: 39.7–76.6%), and OS at 5 years was 20.7% (95% CI: 10.1–42.2%). Conclusions: The long-term survival of DC therapy in MPM in these three trials is promising, which is the basis for the randomized phase II/III DENIM study. This DENIM study is currently enrolling, and the results of which have to be awaited for definite conclusions.

scholarly journals Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer

2011 ◽  
Vol 20 (10) ◽  
pp. 2183-2194 ◽  
Author(s):  
Rebecca Roylance ◽  
David Endesfelder ◽  
Patricia Gorman ◽  
Rebecca A. Burrell ◽  
Jil Sander ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Analysis ◽  
Primary Breast Cancer ◽  
Chromosomal Instability ◽  
Term Survival ◽  
Long Term Survival ◽  
Relationship Of
Sign in / Sign up

Export Citation Format

Share Document